AXIMRIS XR
Live / Allowed — First extension granted (statement of use) (as of 02 Jun 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 23 Jun 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99247604
- Mark type
- Word mark
- Filed
- 23 Jun 2025
- Published for opposition
- 16 Dec 2025
Goods and services
- Class 005 — Pharmaceuticals: Drug delivery systems comprising controlled timed-release and/or targeted-release pharmaceutical formulations, provided as integral components of pharmaceutical preparations; pharmaceutical preparations incorporating such drug delivery systems in the form of oral solid dosage units, namely tablets and capsules; all for use in the treatment of attention deficit disorders, central nervous system disorders, depression, diabetes, epilepsy, gastric and gastrointestinal tract disorders, hypertension, infection, inflammation, pain, rheumatoid arthritis, and rhinitis.
Owner
- Zurich Pharma INC, SOUTHFIELD, MI, US
- Zurich Pharma INC, SOUTHFIELD, MI, US
Prosecution history
- 02 Jun 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Jun 2026 — SOU EXTENSION 1 GRANTED
- 02 Jun 2026 — SOU EXTENSION 1 FILED
- 02 Jun 2026 — SOU TEAS EXTENSION RECEIVED
- 10 Feb 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 16 Dec 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 16 Dec 2025 — PUBLISHED FOR OPPOSITION
- 10 Dec 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Nov 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 17 Nov 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 17 Nov 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 17 Nov 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 17 Nov 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 17 Nov 2025 — NON-FINAL ACTION E-MAILED
- 17 Nov 2025 — NON-FINAL ACTION WRITTEN